Abstract: The pathogenesis of Alzheimer’s disease (AD) is somewhat complex and has yet to be fully understood. As the effectiveness of the therapy currently available for AD has proved to be limited, the need for new drugs has become increasingly urgent. The modulation of the endogenous cannabinoid system (ECBS) is one of the potential therapeutic approaches that is attracting a grow- ing amount of interest. The ECBS consists of endogenous compounds and receptors. The receptors CB1 and CB2 have already been well characterized: CB1 receptors, which are abundant in the brain, particularly in the hippocampus, basal ganglia and cerebellum, regulate memory function and cognition. It has been suggested that the activation of CB1 receptors reduces intracellular Ca con- centrations, inhibits glutamate release and enhances neurotrophin expression and neurogenesis. CB2 receptors are expressed, though to a lesser extent, in the central nervous system, particularly in the microglia and immune system cells involved in the release of cytokines. CB2 receptors have been shown to be upregulated in neuritic plaque-associated microglia in the hippocampus and entorhinal cortex of patients, which suggests that these receptors play a role in the inflammatory pathology of AD. The role of the ECBS in AD is supported by cellular and animal models. By contrast, few clinical studies designed to investigate therapies aimed at reducing behaviour disturbances, espe- cially night-time agitation, eating behaviour and aggressiveness, have yielded positive results. In this review, we will describe how the manipulation of the ECBS offers a potential approach to the treatment of AD.

Modulation of the cannabinoid system. a new perspective for the treatment of the Alzheimer's disease / Talarico, Giuseppina; Trebbastoni, Alessandro; Bruno, Giuseppe; DE LENA, Carlo. - In: CURRENT NEUROPHARMACOLOGY. - ISSN 1570-159X. - 17:2(2018), pp. 176-183. [10.2174/1570159X16666180702144644]

Modulation of the cannabinoid system. a new perspective for the treatment of the Alzheimer's disease

Talarico Giuseppina;Trebbastoni Alessandro;Bruno Giuseppe;de Lena Carlo
2018

Abstract

Abstract: The pathogenesis of Alzheimer’s disease (AD) is somewhat complex and has yet to be fully understood. As the effectiveness of the therapy currently available for AD has proved to be limited, the need for new drugs has become increasingly urgent. The modulation of the endogenous cannabinoid system (ECBS) is one of the potential therapeutic approaches that is attracting a grow- ing amount of interest. The ECBS consists of endogenous compounds and receptors. The receptors CB1 and CB2 have already been well characterized: CB1 receptors, which are abundant in the brain, particularly in the hippocampus, basal ganglia and cerebellum, regulate memory function and cognition. It has been suggested that the activation of CB1 receptors reduces intracellular Ca con- centrations, inhibits glutamate release and enhances neurotrophin expression and neurogenesis. CB2 receptors are expressed, though to a lesser extent, in the central nervous system, particularly in the microglia and immune system cells involved in the release of cytokines. CB2 receptors have been shown to be upregulated in neuritic plaque-associated microglia in the hippocampus and entorhinal cortex of patients, which suggests that these receptors play a role in the inflammatory pathology of AD. The role of the ECBS in AD is supported by cellular and animal models. By contrast, few clinical studies designed to investigate therapies aimed at reducing behaviour disturbances, espe- cially night-time agitation, eating behaviour and aggressiveness, have yielded positive results. In this review, we will describe how the manipulation of the ECBS offers a potential approach to the treatment of AD.
2018
cannabinoid; alzheimer's disease; treatment
01 Pubblicazione su rivista::01a Articolo in rivista
Modulation of the cannabinoid system. a new perspective for the treatment of the Alzheimer's disease / Talarico, Giuseppina; Trebbastoni, Alessandro; Bruno, Giuseppe; DE LENA, Carlo. - In: CURRENT NEUROPHARMACOLOGY. - ISSN 1570-159X. - 17:2(2018), pp. 176-183. [10.2174/1570159X16666180702144644]
File allegati a questo prodotto
File Dimensione Formato  
Talarico_modulation-of-the-cannabinoid-system_2018.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 549.78 kB
Formato Adobe PDF
549.78 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1208240
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 37
social impact